GH-002 is under clinical development by GH Research and currently in Phase I for Treatment Resistant Depression. According to GlobalData, Phase I drugs for Treatment Resistant Depression have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how GH-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GH-002 overview

GH-002 is under development for the treatment of treatment resistant depression and unspecified neurological disorders. The drug candidate is an injectable formulation of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). It acts by targeting serotonin 5HT1A and 5HT2A. It is administered through intravenous bolus route.

GH Research overview

GH Research biopharmaceutical company developing novel therapies for psychiatric and neurological disorders. The company has desigend its proprietary inhalable 5-MeO-DMT for depression. GH Research is headquartered in Dublin, Ireland.

For a complete picture of GH-002’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.